HCAT (Health Catalyst, Inc Common Stock) Stock Analysis - Analyst Ratings

Health Catalyst, Inc Common Stock (HCAT) is a publicly traded Healthcare sector company. As of May 21, 2026, HCAT trades at $1.29 with a market cap of $93.85M and a P/E ratio of -0.34. HCAT moved +2.36% today. Year to date, HCAT is -43.67%; over the trailing twelve months it is -67.26%. Its 52-week range spans $0.96 to $9.24. Analyst consensus is neutral with an average price target of $2.11. Rallies surfaces HCAT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate HCAT?

9 analysts cover HCAT: 0 strong buy, 2 buy, 7 hold, 0 sell, and 0 strong sell. The consensus rating is neutral. The average price target is $2.11.

HCAT Key Metrics

Key financial metrics for HCAT
MetricValue
Price$1.29
Market Cap$93.85M
P/E Ratio-0.34
EPS$-3.74
Dividend Yield0.00%
52-Week High$9.24
52-Week Low$0.96
Volume0
Avg Volume0
Revenue (TTM)$302.48M
Net Income$-265.26M
Gross Margin0.00%

HCAT Analyst Consensus

9 analysts cover HCAT: 0 strong buy, 2 buy, 7 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $2.11.

Latest HCAT News

Recent HCAT Insider Trades

  • Landry Benjamin sold 27.43K (~$72.33K) on Dec 5, 2025.
  • Larson-Green Julie sold 48.00K (~$128.35K) on Dec 4, 2025.
  • Landry Benjamin sold 6.17K (~$20.70K) on Sep 5, 2025.

Common questions about HCAT

What do analysts rate HCAT?
9 analysts cover HCAT: 0 strong buy, 2 buy, 7 hold, 0 sell, and 0 strong sell. The consensus rating is neutral. The average price target is $2.11.
Does Rallies show HCAT price targets?
Yes. Rallies tracks HCAT analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is HCAT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for HCAT. It does not provide personalized investment advice.
HCAT

HCAT